Agricultural Biotechnology: Myth and Measurement

J. Mclaren

DOI: https://doi.org/10.1007/BF03262086

2000-12-01

Abstract:

What problem does this paper attempt to address?

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Ping Liu,Lingxiao Li,Fangping He,Fanxia Meng,Xiaoyan Liu,Yujie Su,Xinhui Su,Benyan Luo,Guoping Peng

DOI: https://doi.org/10.3390/ijms241814225

IF: 5.6

2023-01-01

International Journal of Molecular Sciences

Abstract:Alzheimer's disease (AD) is the most prevalent form of dementia among elderly people worldwide. Cerebrospinal fluid (CSF) is the optimal fluid source for AD biomarkers, while serum biomarkers are much more achievable. To search for novel diagnostic AD biomarkers, we performed a quantitative proteomic analysis of CSF and serum samples from AD and normal cognitive controls (NC). CSF and serum proteomes were analyzed via data-independent acquisition quantitative mass spectrometry. Our bioinformatic analysis was based on Gene Ontology (GO) functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. In comparison to the controls, 8 proteins were more abundant in AD CSF, and 60 were less abundant in AD CSF, whereas 55 proteins were more and 10 were less abundant in the serum samples. ATPase-associated activity for CSF and mitochondrial functions for CSF and serum were the most enriched GO terms of the DEPs. KEGG enrichment analysis showed that the most significant pathways for the differentially expressed proteins were the N-glycan biosynthesis pathways. The area under the curve (AUC) values for CSF sodium-/potassium-transporting ATPase subunit beta-1 (AT1B1), serglycin (SRGN), and thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3) were 0.867 (p = 0.004), 0.833 (p = 0.008), and 0.783 (p = 0.025), respectively. A panel of the above three CSF proteins accurately differentiated AD (AUC = 0.933, p = 0.001) from NC. The AUC values for serum probable phospholipid-transporting ATPase IM (AT8B4) and SRGN were moderate. The AUC of the CSF SRGN + serum SRGN was 0.842 (p = 0.007). These novel AD biomarker candidates are mainly associated with inflammation, ATPase activity, oxidative stress, and mitochondrial dysfunction. Further studies are needed to investigate the molecular mechanisms by which these potential biomarkers are involved in AD.
Identifying Shared Diagnostic Genes and Mechanisms in Vascular Dementia and Alzheimer's Disease Via Bioinformatics and Machine Learning

Shu Wan,Wanning Zheng,Dongdong Lin,Shunan Shi,Jiayi Ren,Jiong Wu,Ming Wang

DOI: https://doi.org/10.1177/25424823241289804

2024-01-01

Journal of Alzheimer's Disease Reports

Abstract:Background Alzheimer's disease (AD) and vascular dementia (VaD) share overlapping pathophysiological characteristics, yet comparative genetic studies are rare. Understanding these overlaps may aid in identifying common diagnostic markers and therapeutic targets. Objective This study identifies shared diagnostic genes and mechanisms linking AD and VaD. Methods Datasets GSE5281 and GSE122063 from the GEO database were used to identify differentially expressed genes (DEGs). Intersection DEGs were analyzed using KEGG and GO enrichment to explore signaling pathways. A PPI network was constructed, and LASSO and SVM-RFE were applied to identify core genes. CIBERSORT assessed immune cell composition and their relationship with core genes. Diagnostic efficacy was evaluated using ROC curves, nomogram, and Decision Curve Analysis (DCA). Core genes were used to identify characteristic genes in various brain regions of AD patients. Results The analysis identified 9021 DEGs for AD and 373 DEGs for VaD, with 74 co-expressed genes and 8 core genes. ROC curves, nomogram, and DCA indicated high diagnostic accuracy. Core gene analysis revealed differential expression of characteristic genes in various brain regions of AD patients. Conclusions This research identified 74 co-expressed genes and 8 pivotal diagnostic genes. These genes likely play roles in signal transduction, neuroinflammation, and autophagy in both AD and VaD. The findings offer potential targets for future research and clinical interventions. Further research should use larger, more diverse datasets and incorporate custom NGS panels to identify novel genetic variants, enhancing precise diagnostic and therapeutic strategies.
Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease

Qi Zhang,Cheng Ma,Marla Gearing,Peng George Wang,Lih-Shen Chin,Lian Li

DOI: https://doi.org/10.1186/s40478-018-0524-2

2018-03-01

Acta Neuropathologica Communications

Abstract:Although the genetic causes for several rare, familial forms of Alzheimer’s disease (AD) have been identified, the etiology of the sporadic form of AD remains unclear. Here, we report a systems-level study of disease-associated proteome changes in human frontal cortex of sporadic AD patients using an integrated approach that combines mass spectrometry-based quantitative proteomics, differential expression analysis, and co-expression network analysis. Our analyses of 16 human brain tissues from AD patients and age-matched controls showed organization of the cortical proteome into a network of 24 biologically meaningful modules of co-expressed proteins. Of these, 5 modules are positively correlated to AD phenotypes with hub proteins that are up-regulated in AD, and 6 modules are negatively correlated to AD phenotypes with hub proteins that are down-regulated in AD. Our study generated a molecular blueprint of altered protein networks in AD brain and uncovered the dysregulation of multiple pathways and processes in AD brain, including altered proteostasis, RNA homeostasis, immune response, neuroinflammation, synaptic transmission, vesicular transport, cell signaling, cellular metabolism, lipid homeostasis, mitochondrial dynamics and function, cytoskeleton organization, and myelin-axon interactions. Our findings provide new insights into AD pathogenesis and suggest novel candidates for future diagnostic and therapeutic development.

neurosciences
Revealing the Molecular Mechanisms of Alzheimer’s Disease Based on Network Analysis

Abdulahad Bayraktar,Simon Lam,Ozlem Altay,Xiangyu Li,Meng Yuan,Cheng Zhang,Muhammad Arif,Hasan Turkez,Mathias Uhlén,Saeed Shoaie,Adil Mardinoglu

DOI: https://doi.org/10.3390/ijms222111556

IF: 5.6

2021-10-26

International Journal of Molecular Sciences

Abstract:The complex pathology of Alzheimer’s disease (AD) emphasises the need for comprehensive modelling of the disease, which may lead to the development of efficient treatment strategies. To address this challenge, we analysed transcriptome data of post-mortem human brain samples of healthy elders and individuals with late-onset AD from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) and Mayo Clinic (MayoRNAseq) studies in the AMP-AD consortium. In this context, we conducted several bioinformatics and systems medicine analyses including the construction of AD-specific co-expression networks and genome-scale metabolic modelling of the brain in AD patients to identify key genes, metabolites and pathways involved in the progression of AD. We identified AMIGO1 and GRPRASP2 as examples of commonly altered marker genes in AD patients. Moreover, we found alterations in energy metabolism, represented by reduced oxidative phosphorylation and ATPase activity, as well as the depletion of hexanoyl-CoA, pentanoyl-CoA, (2E)-hexenoyl-CoA and numerous other unsaturated fatty acids in the brain. We also observed that neuroprotective metabolites (e.g., vitamins, retinoids and unsaturated fatty acids) tend to be depleted in the AD brain, while neurotoxic metabolites (e.g., β-alanine, bilirubin) were more abundant. In summary, we systematically revealed the key genes and pathways related to the progression of AD, gained insight into the crucial mechanisms of AD and identified some possible targets that could be used in the treatment of AD.

biochemistry & molecular biology,chemistry, multidisciplinary
Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression

Bing Bai,Xusheng Wang,Yuxin Li,Ping-Chung Chen,Kaiwen Yu,Kaushik Kumar Dey,Jay M. Yarbro,Xian Han,Brianna M. Lutz,Shuquan Rao,Yun Jiao,Jeffrey M. Sifford,Jonghee Han,Minghui Wang,Haiyan Tan,Timothy Shaw,Ji-Hoon Cho,Suiping Zhou,Hong Wang,Mingming Niu,Ariana Mancieri,Kaitlynn A. Messler,Xiaojun Sun,Zhiping Wu,Vishwajeeth Pagala,Anthony A. High,Wenjian Bi,Hui Zhang,Hongbo Chi,Vahram Haroutunian,Bin Zhang,Thomas G. Beach,Gang Yu,Junmin Peng

DOI: https://doi.org/10.1016/j.neuron.2019.12.015

IF: 16.2

2020-01-01

Neuron

Abstract:Alzheimer's disease (AD) displays a long asymptomatic stage before dementia. We characterize AD stage-associated molecular networks by profiling 14,513 proteins and 34,173 phosphosites in the human brain with mass spectrometry, highlighting 173 protein changes in 17 pathways. The altered proteins are validated in two independent cohorts, showing partial RNA dependency. Comparisons of brain tissue and cerebrospinal fluid proteomes reveal biomarker candidates. Combining with 5xFAD mouse analysis, we determine 15 Aβ-correlated proteins (e.g., MDK, NTN1, SMOC1, SLIT2, and HTRA1). 5xFAD shows a proteomic signature similar to symptomatic AD but exhibits activation of autophagy and interferon response and lacks human-specific deleterious events, such as downregulation of neurotrophic factors and synaptic proteins. Multi-omics integration prioritizes AD-related molecules and pathways, including amyloid cascade, inflammation, complement, WNT signaling, TGF-β and BMP signaling, lipid metabolism, iron homeostasis, and membrane transport. Some Aβ-correlated proteins are colocalized with amyloid plaques. Thus, the multilayer omics approach identifies protein networks during AD progression.
Network Medicine Approach for Analysis of Alzheimer's Disease Gene Expression Data.

David Cohen,Alexander Pilozzi,Xudong Huang

DOI: https://doi.org/10.3390/ijms21010332

IF: 5.6

2020-01-01

International Journal of Molecular Sciences

Abstract:Alzheimer's disease (AD) is the most widespread diagnosed cause of dementia in the elderly. It is a progressive neurodegenerative disease that causes memory loss as well as other detrimental symptoms that are ultimately fatal. Due to the urgent nature of this disease, and the current lack of success in treatment and prevention, it is vital that different methods and approaches are applied to its study in order to better understand its underlying mechanisms. To this end, we have conducted network-based gene co-expression analysis on data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. By processing and filtering gene expression data taken from the blood samples of subjects with varying disease states and constructing networks based on that data to evaluate gene relationships, we have been able to learn about gene expression correlated with the disease, and we have identified several areas of potential research interest.
PROBLEMS OF HUMAN NUTRITION IN NIGERIA.

O. Bassir

1965-04-01

Abstract:
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery

Bing Bai,David Vanderwall,Yuxin Li,Xusheng Wang,Suresh Poudel,Hong Wang,Kaushik Kumar Dey,Ping-Chung Chen,Ka Yang,Junmin Peng

DOI: https://doi.org/10.1186/s13024-021-00474-z

2021-08-12

Molecular Neurodegeneration

Abstract:Abstract Mass spectrometry-based proteomics empowers deep profiling of proteome and protein posttranslational modifications (PTMs) in Alzheimer’s disease (AD). Here we review the advances and limitations in historic and recent AD proteomic research. Complementary to genetic mapping, proteomic studies not only validate canonical amyloid and tau pathways, but also uncover novel components in broad protein networks, such as RNA splicing, development, immunity, membrane transport, lipid metabolism, synaptic function, and mitochondrial activity. Meta-analysis of seven deep datasets reveals 2,698 differentially expressed (DE) proteins in the landscape of AD brain proteome ( n = 12,017 proteins/genes), covering 35 reported AD genes and risk loci. The DE proteins contain cellular markers enriched in neurons, microglia, astrocytes, oligodendrocytes, and epithelial cells, supporting the involvement of diverse cell types in AD pathology. We discuss the hypothesized protective or detrimental roles of selected DE proteins, emphasizing top proteins in “amyloidome” (all biomolecules in amyloid plaques) and disease progression. Comprehensive PTM analysis represents another layer of molecular events in AD. In particular, tau PTMs are correlated with disease stages and indicate the heterogeneity of individual AD patients. Moreover, the unprecedented proteomic coverage of biofluids, such as cerebrospinal fluid and serum, procures novel putative AD biomarkers through meta-analysis. Thus, proteomics-driven systems biology presents a new frontier to link genotype, proteotype, and phenotype, accelerating the development of improved AD models and treatment strategies.

neurosciences
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

Jiansong Fang,Andrew A. Pieper,Ruth Nussinov,Garam Lee,Lynn Bekris,James B. Leverenz,Jeffrey Cummings,Feixiong Cheng

DOI: https://doi.org/10.1002/med.21709

2020-07-13

Medicinal Research Reviews

Abstract:Following two decades of more than 400 clinical trials centered on the "one drug, one target, one disease" paradigm, there is still no effective disease‐modifying therapy for Alzheimer's disease (AD). The inherent complexity of AD may challenge this reductionist strategy. Recent observations and advances in network medicine further indicate that AD likely shares common underlying mechanisms and intermediate pathophenotypes, or endophenotypes, with other diseases. In this review, we consider AD pathobiology, disease comorbidity, pleiotropy, and therapeutic development, and construct relevant endophenotype networks to guide future therapeutic development. Specifically, we discuss six main endophenotype hypotheses in AD: amyloidosis, tauopathy, neuroinflammation, mitochondrial dysfunction, vascular dysfunction, and lysosomal dysfunction. We further consider how this endophenotype network framework can provide advances in computational and experimental strategies for drug‐repurposing and identification of new candidate therapeutic strategies for patients suffering from or at risk for AD. We highlight new opportunities for endophenotype‐informed, drug discovery in AD, by exploiting multi‐omics data. Integration of genomics, transcriptomics, radiomics, pharmacogenomics, and interactomics (protein–protein interactions) are essential for successful drug discovery. We describe experimental technologies for AD drug discovery including human induced pluripotent stem cells, transgenic mouse/rat models, and population‐based retrospective case–control studies that may be integrated with multi‐omics in a network medicine methodology. In summary, endophenotype‐based network medicine methodologies will promote AD therapeutic development that will optimize the usefulness of available data and support deep phenotyping of the patient heterogeneity for personalized medicine in AD.

pharmacology & pharmacy,chemistry, medicinal
A deep belief network-based method to identify proteomic risk markers for Alzheimer disease

Ning An,Liuqi Jin,Huitong Ding,Jiaoyun Yang,Jing Yuan

DOI: https://doi.org/10.48550/arXiv.2003.05776

2020-03-11

Quantitative Methods

Abstract:While a large body of research has formally identified apolipoprotein E (APOE) as a major genetic risk marker for Alzheimer disease, accumulating evidence supports the notion that other risk markers may exist. The traditional Alzheimer-specific signature analysis methods, however, have not been able to make full use of rich protein expression data, especially the interaction between attributes. This paper develops a novel feature selection method to identify pathogenic factors of Alzheimer disease using the proteomic and clinical data. This approach has taken the weights of network nodes as the importance order of signaling protein expression values. After generating and evaluating the candidate subset, the method helps to select an optimal subset of proteins that achieved an accuracy greater than 90%, which is superior to traditional machine learning methods for clinical Alzheimer disease diagnosis. Besides identifying a proteomic risk marker and further reinforce the link between metabolic risk factors and Alzheimer disease, this paper also suggests that apidonectin-linked pathways are a possible therapeutic drug target.
Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1+AβPP mouse model of Alzheimer's disease

Brian A. Soreghan,Bing-Wen Lu,Stefani N. Thomas,Karen Duff,Eugene A. Rakhmatulin,Tatiana Nikolskaya,Ting Chen,Austin J. Yang

DOI: https://doi.org/10.3233/jad-2005-8302

2005-01-01

Abstract:Increasing evidence suggests that oxidative injury is involved in the pathogenesis of many age-related neurodegenerative disorders, including Alzheimer's disease (AD). Identifying the protein targets of oxidative stress is critical to determine which proteins may be responsible for the neuronal impairments and subsequent cell death that occurs in AD. In this study, we have applied a high-throughput shotgun proteomic approach to identify the targets of protein carbonylation in both aged and PS1 + AbetaPP transgenic mice. However, because of the inherent difficulties associated with proteomic database searching algorithms, several newly developed bioinformatic tools were implemented to ascertain a probability-based discernment between correct protein assignments and false identifications to improve the accuracy of protein identification. Assigning a probability to each identified peptide/protein allows one to objectively monitor the expression and relative abundance of particular proteins from diverse samples, including tissue from transgenic mice of mixed genetic backgrounds. This robust bioinformatic approach also permits the comparison of proteomic data generated by different laboratories since it is instrument- and database-independent. Applying these statistical models to our initial studies, we detected a total of 117 oxidatively modified (carbonylated) proteins, 59 of which were specifically associated with PS1 + AbetaPP mice. Pathways and network component analyses suggest that there are three major protein networks that could be potentially altered in PS1 + AbetaPP mice as a result of oxidative modifications. These pathways are 1) iNOS-integrin signaling pathway, 2) CRE/CBP transcription regulation and 3) rab-lyst vesicular trafficking. We believe the results of these studies will help establish an initial AD database of oxidatively modified proteins and provide a foundation for the design of future hypothesis driven research in the areas of aging and neurodegeneration.
An Integrated Genetics Approach for Identifying Protein Signal Pathways of Alzheimer's Disease

Yue Huang,Xuezhi Sun,Guangshu Hu

DOI: https://doi.org/10.1080/10255842.2010.482525

2011-01-01

Abstract:Alzheimer's disease (AD) is considered one of the most common age-associated neurodegenerative disorders, affecting millions of senior people worldwide. Combination of protein-protein interaction (PPI) network analysis and gene expression studies provides a better insight into AD. A computational approach was developed in our work to identify protein signal pathways between amyloid precursor proteins and tau proteins, which are well known as important proteins for AD. First, a modified LA-SEN method, called the network-constrained regularisation analysis, was applied to microarray data from a transgenic mouse model and AD patients. Then protein pathways were constructed based on an integer linear programming model to integrate microarray data and the PPI database. Important pathways of AD, including some cancer-related pathways, were identified finally.
Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Erik C. B. Johnson,Eric B. Dammer,Duc M. Duong,Luming Yin,Madhav Thambisetty,Juan C. Troncoso,James J. Lah,Allan I. Levey,Nicholas T. Seyfried

DOI: https://doi.org/10.1186/s13024-018-0282-4

2018-10-04

Molecular Neurodegeneration

Abstract:BackgroundThe complicated cellular and biochemical changes that occur in brain during Alzheimer’s disease are poorly understood. In a previous study we used an unbiased label-free quantitative mass spectrometry-based proteomic approach to analyze these changes at a systems level in post-mortem cortical tissue from patients with Alzheimer’s disease (AD), asymptomatic Alzheimer’s disease (AsymAD), and controls. We found modules of co-expressed proteins that correlated with AD phenotypes, some of which were enriched in proteins identified as risk factors for AD by genetic studies.MethodsThe amount of information that can be obtained from such systems-level proteomic analyses is critically dependent upon the number of proteins that can be quantified across a cohort. We report here a new proteomic systems-level analysis of AD brain based on 6,533 proteins measured across AD, AsymAD, and controls using an analysis pipeline consisting of isobaric tandem mass tag (TMT) mass spectrometry and offline prefractionation.ResultsOur new TMT pipeline allowed us to more than double the depth of brain proteome coverage. This increased depth of coverage greatly expanded the brain protein network to reveal new protein modules that correlated with disease and were unrelated to those identified in our previous network. Differential protein abundance analysis identified 350 proteins that had altered levels between AsymAD and AD not caused by changes in specific cell type abundance, potentially reflecting biochemical changes that are associated with cognitive decline in AD. RNA binding proteins emerged as a class of proteins altered between AsymAD and AD, and were enriched in network modules that correlated with AD pathology. We developed a proteogenomic approach to investigate RNA splicing events that may be altered by RNA binding protein changes in AD. The increased proteome depth afforded by our TMT pipeline allowed us to identify and quantify a large number of alternatively spliced protein isoforms in brain, including AD risk factors such as BIN1, PICALM, PTK2B, and FERMT2. Many of the new AD protein network modules were enriched in alternatively spliced proteins and correlated with molecular markers of AD pathology and cognition.ConclusionsFurther analysis of the AD brain proteome will continue to yield new insights into the biological basis of AD.

neurosciences
Integrative Metabolomics-Genomics Approach Reveals Key Metabolic Pathways and Regulators of Alzheimer's Disease

Emrin Horgusluoglu,Ryan Neff,Won-Min Song,Minghui Wang,Qian Wang,Matthias Arnold,Jan Krumsiek,Beatriz Galindo-Prieto,Chen Ming,Kwangsik Nho,Gabi Kastenmueller,Xianlin Han,Rebecca Baillie,Qi Zeng,Shea Andrews,Haoxiang Cheng,Ke Hao,Alison Goate,David A. Bennett,Andrew J. Saykin,Rima Kaddurah-Daouk,Bin Zhang

DOI: https://doi.org/10.1002/alz.12468

2022-01-01

Alzheimer s & Dementia

Abstract:Metabolites, the biochemical products of the cellular process, can be used to measure alterations in biochemical pathways related to the pathogenesis of Alzheimer's disease (AD). However, the relationships between systemic abnormalities in metabolism and the pathogenesis of AD are poorly understood. In this study, we aim to identify AD-specific metabolomic changes and their potential upstream genetic and transcriptional regulators through an integrative systems biology framework for analyzing genetic, transcriptomic, metabolomic, and proteomic data in AD. Metabolite co-expression network analysis of the blood metabolomic data in the Alzheimer's Disease Neuroimaging Initiative (ADNI) shows short-chain acylcarnitines/amino acids and medium/long-chain acylcarnitines are most associated with AD clinical outcomes, including episodic memory scores and disease severity. Integration of the gene expression data in both the blood from the ADNI and the brain from the Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) program reveals ABCA1 and CPT1A are involved in the regulation of acylcarnitines and amino acids in AD. Gene co-expression network analysis of the AMP-AD brain RNA-seq data suggests the CPT1A- and ABCA1-centered subnetworks are associated with neuronal system and immune response, respectively. Increased ABCA1 gene expression and adiponectin protein, a regulator of ABCA1, correspond to decreased short-chain acylcarnitines and amines in AD in the ADNI. In summary, our integrated analysis of large-scale multiomics data in AD systematically identifies novel metabolites and their potential regulators in AD and the findings pave a way for not only developing sensitive and specific diagnostic biomarkers for AD but also identifying novel molecular mechanisms of AD pathogenesis.
Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

Ya-Nan Ou,Yu-Xiang Yang,Yue-Ting Deng,Can Zhang,Hao Hu,Bang-Sheng Wu,Yi Liu,Yan-Jiang Wang,Ying Zhu,John Suckling,Lan Tan,Jin-Tai Yu

DOI: https://doi.org/10.1038/s41380-021-01251-6

2023-01-01

Alzheimer s & Dementia

Abstract:Genome-wide association studies (GWASs) have discovered numerous risk genes for Alzheimer's disease (AD), but how these genes confer AD risk is challenging to decipher. To efficiently transform genetic associations into drug targets for AD, we employed an integrative analytical pipeline using proteomes in the brain and blood by systematically applying proteome-wide association study (PWAS), Mendelian randomization (MR) and Bayesian colocalization. Collectively, we identified the brain protein abundance of 7 genes (ACE, ICA1L, TOM1L2, SNX32, EPHX2, CTSH, and RTFDC1) are causal in AD (P < 0.05/proteins identified for PWAS and MR; PPH4 >80% for Bayesian colocalization). The proteins encoded by these genes were mainly expressed on the surface of glutamatergic neurons and astrocytes. Of them, ACE with its protein abundance was also identified in significant association with AD on the blood-based studies and showed significance at the transcriptomic level. SNX32 was also found to be associated with AD at the blood transcriptomic level. Collectively, our current study results on genetic, proteomic, and transcriptomic approaches has identified compelling genes, which may provide important leads to design future functional studies and potential drug targets for AD.
ACCELERATING MEDICINES PARTNERSHIP: CO-EXPRESSION NETWORKS

Minghui Wang,Panos Roussos,Andrew McKenzie,Pavel Katsel,Patrizia Casaccia,Eric E. Schadt,Vahram Haroutunian,Bin Zhang

DOI: https://doi.org/10.1016/j.jalz.2016.06.586

2016-01-01

Alzheimer s & Dementia

Abstract:Alzheimer's disease (AD) is the most common form of degenerative dementia and is expected to affect over 100 million people worldwide in 2050. Genetic, pathological, neuroimaging data reveal that AD involves many different pathways across many different brain tissues. However, the molecular basis of AD development and progression remains elusive. Increasingly available large scale genetic, genomic, proteomic and pathophysiological data in AD have made it possible to more comprehensively address the complex mechanisms and effectors of AD through application of advanced systems biology approaches. We have developed a multiscale network modeling approach (MNMA) to integrate multi-Omics data in AD. MNMA integrates not only genetic and gene expression data into causal networks but also causal and coexpression networks for discovery of key subnetworks and causal regulators in AD. We constructed gene regulatory networks from about 2500 postmortem brain tissue samples across 19 brain regions from AD and normal control subjects. Thousands of gene subnetworks were identified and systematically examined with respect to known pathways, AD related gene sets, and AD clinical and pathophysiological data. These subnetworks were rank-ordered by the degree of dysregulation and relevance to AD pathology. We found that a microglia/immune enriched network was most strongly associated with late-onset AD while the dysregulation of an oligodendrocyte and myelination-enriched network was one of the early events in the development of AD. We observed that immune response subnetworks were highly correlated among all the brain regions we studied, suggesting that immune response is regulated in a coordinated way in different areas of the brain and/or as a result of AD progression throughout the brain. This finding is consistent with the finding of AD genome wide studies that more than one third of genes implicated in AD risk are part of immune response pathways. Our integrative network analysis provides a global landscape of molecular interactions in multiple brain regions of Alzheimer’s disease, which is critical for us to understand objectively and comprehensively how various molecular pathways interplay with each other within and across different brain regions to give rise to the disease.
Hippocampus proteomics and brain lipidomics reveal network dysfunction and lipid molecular abnormalities in APP/PS1 mouse model of Alzheimer's disease.

Wen Tan,Weiwei Liu,Yan Cao,Xueju Zhang

DOI: https://doi.org/10.1021/acs.jproteome.0c00255

2020-06-08

Journal of Proteome Research

Abstract:Alzheimer's Disease (AD) is closely related to protein dysfunction and aberrant lipid metabolism in brain. Our study could contribute to the discovery of lipid and protein biomarkers for early diagnosis and therapy. In current work, novel quantitative proteomic and lipidomic methods were developed for the characterization of molecular perturbation occurring in brain in early-stage AD mice. For the purpose, we performed a proteomic and lipidomic screening by liquid chromatography with mass spectrometry. Significant changes were detected including 231 proteins and 11 lipid compounds in AD mouse brain. Early-stage AD disturbed biological pathways implicating in neuroactive ligand-receptor, complement and coagulation cascades, PI3K-Akt signaling and metabolic pathways and glycerophospholipid metabolism. The results in current study suggest that these significantly altered proteins and lipids may be involved in the early stage of AD. Our work raises possibility of AD diagnosis and therapy by new protein targets and lipid biomarkers.

Medicine,Biology
Subcellular proteomics insights into Alzheimer's disease development

Zhiyuan Liang,Hongbin Zhuang,Xueshan Cao,Guanwei Ma,Liming Shen

DOI: https://doi.org/10.1002/prca.202200112

Abstract:Alzheimer's disease (AD), one of the most common dementias, is a neurodegenerative disease characterized by cognitive impairment and decreased judgment function. The expected number of AD patient is increasing in the context of the world's advancing medical care and increasing human life expectancy. Since current molecular mechanism studies on AD pathogenesis are incomplete, there is no specific and effective therapeutic agent. Mass spectrometry (MS)-based unbiased proteomics studies provide an effective and comprehensive approach. Many advances have been made in the study of the mechanism, diagnostic markers, and drug targets of AD using proteomics. This paper focus on subcellular level studies, reviews studies using proteomics to study AD-associated mitochondrial dysfunction, synaptic, and myelin damage, the protein composition of amyloid plaques (APs) and neurofibrillary tangles (NFTs), changes in tissue extracellular vehicles (EVs) and exosome proteome, and the protein changes in ribosomes and lysosomes. The methods of sample separation and preparation and proteomic analysis as well as the main findings of these studies are involved. The results of these proteomics studies provide insights into the pathogenesis of AD and provide theoretical resource and direction for future research in AD, helping to identify new biomarkers and drugs targets for AD.
Deciphering Early and Progressive Molecular Signatures in Alzheimer's Disease through Integrated Longitudinal Proteomic and Pathway Analysis in a Rodent Model

Hamad Yadikar,Mubeen A. Ansari,Mohamed Abu-Farha,Shibu Joseph,Betty T. Thomas,Fahd Al-Mulla

DOI: https://doi.org/10.3390/ijms25126469

IF: 5.6

2024-06-13

International Journal of Molecular Sciences

Abstract:Alzheimer's disease (AD), the leading cause of dementia worldwide, remains a challenge due to its complex origin and degenerative character. The need for accurate biomarkers and treatment targets hinders early identification and intervention. To fill this gap, we used a novel longitudinal proteome methodology to examine the temporal development of molecular alterations in the cortex of an intracerebroventricular streptozotocin (ICV-STZ)-induced AD mouse model for disease initiation and progression at one, three-, and six-weeks post-treatment. Week 1 revealed metabolic protein downregulation, such as Aldoa and Pgk1. Week 3 showed increased Synapsin-1, and week 6 showed cytoskeletal protein alterations like Vimentin. The biological pathways, upstream regulators, and functional effects of proteome alterations were dissected using advanced bioinformatics methods, including Ingenuity Pathway Analysis (IPA) and machine learning algorithms. We identified Mitochondrial Dysfunction, Synaptic Vesicle Pathway, and Neuroinflammation Signaling as disease-causing pathways. Huntington's Disease Signaling and Synaptogenesis Signaling were stimulated while Glutamate Receptor and Calcium Signaling were repressed. IPA also found molecular connections between PPARGC1B and AGT, which are involved in myelination and possible neoplastic processes, and MTOR and AR, which imply mechanistic involvements beyond neurodegeneration. These results help us comprehend AD's molecular foundation and demonstrate the promise of focused proteomic techniques to uncover new biomarkers and therapeutic targets for AD, enabling personalized medicine.

biochemistry & molecular biology,chemistry, multidisciplinary
Transcriptomic Analysis of Lipid Metabolism Genes in Alzheimer's Disease: Highlighting Pathological Outcomes and Compartmentalized Immune Status

Yue Sun,Mengni Jiang,Xiang Long,Yongzhen Miao,Huanhuan Du,Ting Zhang,Xuejun Ma,Yue Zhang,Hongrui Meng

DOI: https://doi.org/10.1007/s12031-024-02225-3

2024-05-24

Journal of Molecular Neuroscience

Abstract:The dysregulation of lipid metabolism has been strongly associated with Alzheimer's disease (AD) and has intricate connections with various aspects of disease progression, such as amyloidogenesis, bioenergetic deficit, oxidative stress, neuroinflammation, and myelin degeneration. Here, a comprehensive bioinformatic assessment was conducted on lipid metabolism genes in the brains and peripheral blood of AD-derived transcriptome datasets, characterizing the correlation between differentially expressed genes (DEGs) of lipid metabolism and disease pathologies, as well as immune cell preferences. Through the application of weighted gene co-expression network analysis (WGCNA), modules eigengenes related to lipid metabolism were pinpointed, and the examination of their molecular functions within biological processes, molecular pathways, and their associations with pathological phenotypes and molecular networks has been characterized. Analysis of biological networks indicates notable discrepancies in the expression patterns of the DEGs between neuronal and immune cells, as well as variations in cell type enrichments within both brain tissue and peripheral blood. Additionally, drugs targeting the DEGs from central and peripheral and a diagnostic model for hub genes from the blood were retrieved and assessed, some of which were shown to be useful for therapeutic and diagnostic. These results revealed the distinctive pattern of transcriptionally abnormal lipid metabolism in central, peripheral, and immune cell activation, providing valuable insight into lipid metabolism for diagnosing and guiding more effective treatment for AD.

biochemistry & molecular biology,neurosciences

Agricultural Biotechnology: Myth and Measurement

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Identifying Shared Diagnostic Genes and Mechanisms in Vascular Dementia and Alzheimer's Disease Via Bioinformatics and Machine Learning

Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease

Revealing the Molecular Mechanisms of Alzheimer’s Disease Based on Network Analysis

Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression

Network Medicine Approach for Analysis of Alzheimer's Disease Gene Expression Data.

PROBLEMS OF HUMAN NUTRITION IN NIGERIA.

Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery

Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

A deep belief network-based method to identify proteomic risk markers for Alzheimer disease

Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1+AβPP mouse model of Alzheimer's disease

An Integrated Genetics Approach for Identifying Protein Signal Pathways of Alzheimer's Disease

Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Integrative Metabolomics-Genomics Approach Reveals Key Metabolic Pathways and Regulators of Alzheimer's Disease

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

ACCELERATING MEDICINES PARTNERSHIP: CO-EXPRESSION NETWORKS

Hippocampus proteomics and brain lipidomics reveal network dysfunction and lipid molecular abnormalities in APP/PS1 mouse model of Alzheimer's disease.

Subcellular proteomics insights into Alzheimer's disease development

Deciphering Early and Progressive Molecular Signatures in Alzheimer's Disease through Integrated Longitudinal Proteomic and Pathway Analysis in a Rodent Model

Transcriptomic Analysis of Lipid Metabolism Genes in Alzheimer's Disease: Highlighting Pathological Outcomes and Compartmentalized Immune Status